Phathom Pharmaceuticals opened patient screening on September 29, 2026 for pHalcon-NERD-302, a Phase 3 trial testing whether vonoprazan taken on-demand works for non-erosive GERD, the form of the disease that accounts for roughly 23 million diagnosed U.S. cases. That is a meaningful design shift: the FDA’s existing VOQUEZNA approvals cover fixed daily dosing, not as-needed use, so the company is effectively asking regulators to sanction a different way patients actually take the drug.
The clinical logic is straightforward. Non-erosive GERD is intermittent by nature: heartburn flares rather than constant acid damage to tissue. A patient who takes a pill only when symptoms appear behaves differently from one on a daily regimen, and that difference matters for both trial design and eventual prescribing. The PHALCON-NERD-301 trial established daily vonoprazan’s efficacy and led to the July 2024 approval. NERD-302 is built around the question that approval left open: does flexible, symptom-driven dosing hold up in a controlled registrational setting?
Topline results from NERD-302 are expected, though the 8-K does not specify a year. That timeline gap is the practical risk here. A registrational trial in a symptom-driven population requires a dense, reliable patient diary infrastructure, and on-demand dosing trials are harder to blind and harder to adjudicate than fixed-schedule ones. Regulators will want to see that patients actually used the drug as instructed, not that they drifted into daily use or stopped recording symptoms consistently. How Phathom handles endpoint verification in the statistical analysis plan will determine whether the data can support a label change rather than just a publication.
The commercial case for a PRN label is real: prescribers and patients often use daily-approved drugs as needed anyway, and a label that matches actual behavior can shift formulary conversations. Watch the topline readout for the proportion of symptom-free days endpoint, which is the most common primary measure in on-demand acid-suppression trials and the number most likely to determine FDA’s posture toward a supplemental approval.
Source link: https://www.sec.gov/Archives/edgar/data/1783183/000119312526407696/d22070d8k.htm
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
